2022 AIPLA PTAB Bench + Bar
August 23, 2022 1:00 PM to 6:00 PM
Location
Clara Barton Auditorium
600 Dulany Street
Alexandria, VA, US
Contact
Email: aipla@aipla.org
Unfortunately, this event has been cancelled.
The PTAB Trial Committee is working to integrate this great content into a number of programs coming up this Fall and in Spring 2023.
Thank you to our sponsors in part!
News
-
.png?sfvrsn=9d645e3f_0 "USPTO")
AIPLA Comments on Ex Parte Reexamination Requirements
August 27, 2026
Alexandria, VA. August 21, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments in response to the USPTO’s Notice of Proposed Rulemaking proposing to require identification of all real parties-in-interest (RPIs) in third-party ex parte reexamination requests. -
AIPLA Comments to the Copyright Office on Alternative Fee Structures for Registration
July 6, 2026
Alexandria, VA. June 24, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the U.S. Copyright Office's Notice of Inquiry regarding alternative copyright registration fee structures. -
AIPLA Comments to the Copyright Office on Group Registration of Updates to a News Website
July 6, 2026
Alexandria, VA. June 29, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments supporting the U.S. Copyright Office's proposed expansion of eligibility for group registration of updates to news websites by removing restrictions that exclude subject-specific publications. -
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
.png?sfvrsn=143e8f56_1 "supreme court")
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc.